Compare NIO Inc. (NIO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Novavax Inc — how do they compare? NIO Inc. trades at $3.58 (market cap $8.62B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: NIO Inc. is far larger — about 4.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and Novavax Inc for 59 Days on average.
| NIO | NVAX | |
|---|---|---|
Market Cap | $8.62B | $1.82B |
Volume | 39,648,517 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $12.56 |
52-Week Low | $3.37 | $6.22 |
Typical Hold Time | 81 Days | 59 Days |
Enterprise Value | $6.52B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.58, up 1.13% in the last session but near a 52-week low amid a bearish technical trend. The company reported Q3 2026 deliveries up 25.4% and recently formed a strategic battery-swap partnership with Geely, yet it continues to post net losses with a -4.17% net margin. Analyst consensus is a 'Buy' with a $6.23 price target, but high debt and negative cash flows pose challenges.
The outlook remains cautious; revenue growth and partnership potential offer upside, but persistent losses, cash burn, and intense EV competition present significant risks. Investors should weigh the long-term battery-swap network expansion against near-term financial instability and market volatility.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
